ISPE Previews Drug Shortages Prevention Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE Previews Drug Shortages Prevention Plan


ISPE announced on Aug. 27 that it released a preview of its Drug Shortages Prevention Plan, developed by ISPE’s Drug Shortages Task Team, aimed at helping the pharmaceutical industry avoid drug shortages, identify root causes, create and sustain organizational cultures, and maintain a robust and reliable supply of medications to patients world-wide. The Introductory Summary to the Plan released on Aug. 27 provides a first look at what is covered in the complete Plan.

“Our goal is that the pharmaceutical industry will use the Plan not only to help them look holistically across the supply chain, but also as a roadmap to use in challenging their current processes, systems and practices and to identify potential gaps and risks,” said ISPE CEO and president, Nancy Berg.

According to Berg, ISPE’s 2013 study on drug shortages provided clear evidence that mitigating shortages requires a holistic approach that includes careful alignment of organizational aspects, people, as well as the technical aspects of process and production in understanding risks and signals indicating a drug shortage may be possible.

The ISPE Drug Shortages Task Team will release the complete Drug Shortages Prevention Plan during the 2014 ISPE Annual Meeting that will be held Oct. 12-15 in Las Vegas, Nevada, US.

Source: ISPE

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here